
Contents

1	Preclinical Foundations: Relevant Anatomy and Physiology	1
1.1	Anatomy and Histology.....	2
1.2	Microanatomy of the Retina.....	4
1.3	Vascular Anatomy.....	13
1.4	Immunology.....	14
1.4.1	Innate Immunity and Toll-Like Receptors.....	14
1.4.2	Adaptive Immunity.....	17
1.5	Pharmacology and Toxicology.....	23
1.5.1	Acid–Base Chemistry.....	23
1.5.2	Dose–Response Relationships.....	24
1.5.3	Pharmacokinetic Relationships.....	24
1.6	Summary of Key Points.....	30
	References.....	30
2	Pharmacology of Chloroquine and Hydroxychloroquine	35
2.1	History.....	35
2.2	Chemistry.....	36
2.3	Pharmacokinetics and Tissue Distribution of the 4-Aminoquinolines.....	39
2.3.1	Absorption.....	39
2.3.2	Distribution and Pharmacokinetics.....	39
2.3.3	Steady-State Concentration of 4-Aminoquinolines in Various Organs.....	41
2.3.4	Metabolism.....	44
2.3.5	Excretion and Storage.....	45
2.4	Clinical Uses and Dosing.....	45
2.5	Pregnancy and Lactation.....	48
2.6	Mechanism of Action.....	49
2.6.1	Positive Studies on Mechanism of Action of 4-Aminoquinolines.....	49
2.6.2	Negative Studies on Mechanism of Action of 4-Aminoquinolines.....	54
2.6.3	Drug Interactions.....	55
2.7	Summary of Key Points.....	55
	References.....	56

3 Toxicology of Hydroxychloroquine and Chloroquine and the Pathology of the Retinopathy They Cause.....	65
3.1 Toxic Concentrations	66
3.2 Mechanism of Toxicity	67
3.3 Nonretinal Ocular Toxicity	68
3.4 Relative Toxicity of Chloroquine and Hydroxychloroquine	69
3.5 Nonocular Toxicity of Chloroquine and Hydroxychloroquine	71
3.6 Pathology of 4-Aminoquinoline Retinopathy and Nonocular Cytopathy	72
3.6.1 Cell Culture and Animal Models.....	72
3.7 Human Pathology	76
3.8 Summary of Key Points.....	78
References.....	79
4 Definitions of Hydroxychloroquine and Chloroquine Retinopathy.....	85
4.1 Summary of Key Points.....	88
References.....	93
5 Epidemiology of Hydroxychloroquine and Chloroquine Retinopathy.....	95
5.1 Demographics of Patients Taking 4-Aminoquinolines.....	96
5.2 Prevalence and Incidence	96
5.3 Summary of Key Points.....	102
References.....	103
6 Natural History of Hydroxychloroquine and Chloroquine Retinopathy.....	107
6.1 Clinical Setting and Picture for Development of Chloroquine and Hydroxychloroquine Retinopathy	107
6.2 Symptoms	108
6.3 Signs of 4-Aminoquinoline Retinopathy	109
6.3.1 Visual Acuity.....	109
6.3.2 Stages of 4-Aminoquinoline Retinopathy	110
6.4 Reversibility.....	120
6.5 Delayed Onset Retinopathy	122
6.6 Progression of Retinopathy.....	122
6.7 Treatment of Retinopathy	124
6.8 Prognosis.....	124
6.9 Summary of Key Points.....	127
References.....	128
7 Risk Factors for Hydroxychloroquine and Chloroquine Retinopathy.....	133
7.1 Age.....	135
7.2 Gender.....	136

7.3	Daily Dose Adjusted for the Lesser of Ideal and Actual Body Weight (Adjusted Daily Dose)	137
7.4	Cumulative Dose.....	143
7.5	Duration.....	145
7.6	Renal Dysfunction.....	145
7.7	Liver Dysfunction	146
7.8	Preexisting Maculopathy.....	146
7.9	Genetic Predisposition and Protection.....	146
7.10	Preexisting Visual Field Abnormalities.....	147
7.11	More Speculative Risk Factors	148
7.12	Combinations of Risk Factors	149
7.13	Summary of Key Points	150
	References.....	151
8	Ancillary Testing in Screening for Hydroxychloroquine and Chloroquine Retinopathy.....	155
8.1	Defining Normal.....	159
8.2	Principles Common to Ancillary Tests Used in Screening for 4-Aminoquinoline Retinopathy	160
8.3	Reproducibility of Ancillary Tests	166
8.4	Establishing a Prior Probability and Bayesian Inference.....	169
8.5	Static Automated Perimetry	169
8.6	Multifocal Electroretinography.....	191
8.6.1	Fundamentals of Multifocal Electroretinography	191
8.6.2	Sources of Variability and Factors That Influence the Multifocal Electroretinogram	194
8.6.3	Normal Values and Reproducibility of the Multifocal Electroretinogram.....	195
8.6.4	Interpretation of Multifocal Electroretinograms	198
8.6.5	Summarizing the Role of Multifocal Electroretinography in Screening for 4-Aminoquinoline Retinopathy	202
8.7	Spectral Domain Optical Coherence Tomography.....	202
8.8	Fundus Autofluorescence	204
8.9	Fluorescein Angiography	211
8.10	Amsler Grid.....	211
8.11	Electrooculogram	213
8.12	Global and Focal Electroretinography	214
8.13	Color Vision Testing.....	215
8.14	Scanning Laser Polarimetry	215
8.15	Multiple Other Failed or Unadopted Ancillary Tests	216
8.16	Relative Sensitivity and Specificity of Ancillary Screening Tests for 4-Aminoquinoline Retinopathy	218
8.17	Challenges.....	219
8.18	Summary of Key Points	220
	References.....	220

9	Screening for Hydroxychloroquine and Chloroquine Retinopathy	227
9.1	Indications for Screening	228
9.2	Baseline Screening	229
9.3	Follow-up Screening Visits	229
9.4	Who Should Screen and What Tests Should Be Used?.....	229
9.5	Number Needed to Screen	236
9.6	Actual Screening Practice	237
9.7	Responses to Positive Results of Screening.....	238
9.8	Cost-Effectiveness of Screening for 4-Aminoquinoline Retinopathy	239
9.9	Medicolegal Aspects of Screening	240
9.10	Patient Education and Home Medical Records.....	241
9.11	Screening After Cessation of Chloroquine of Hydroxychloroquine.....	242
9.12	Challenges	242
9.13	Summary of Key Points	242
	References.....	243
10	Clinical Examples in Managing Patients	
	Taking 4-Aminoquinolines	247
10.1	A Case of Prolonged Toxic Dosing with Evidence of Premaculopathy	247
10.2	The Importance of the Clinical Estimation of Pretest Probability of 4-Aminoquinoline Retinopathy for Proper Interpretation of Ancillary Tests	253
10.3	Hydroxychloroquine Retinopathy Due to Long-Term Overdosing, Misinterpretation of 10-2 Visual Fields, and an Internist's Unresponsiveness to a Recommendation to Stop Medication	253
10.4	A Case of Hydroxychloroquine Retinopathy in an Overdosed, Regularly Monitored Patient in Whom the Fundus Changes Were Atypically Mild and in Which Progression of Damage Occurred Despite Cessation of Drug.....	257
10.5	Hydroxychloroquine Overdosage in a Patient with Renal Failure	258
10.6	Unexpected Location of Retinopathy with Misinterpretation of the SD-OCT in a Chronically Overdosed Patient Taking Hydroxychloroquine	265
10.7	Hydroxychloroquine Monitoring in the Setting of Preexisting Maculopathy	265
10.8	Asymmetric Hydroxychloroquine Retinopathy in an Appropriately Dosed Patient with Progression of Retinopathy After Cessation of the Drug.....	274
10.9	Screening for Hydroxychloroquine Retinopathy in a Setting of Confounding Glaucomatous Visual Field Defects and Preexisting Maculopathy from Resolved Central Retinal Vein Occlusion and Macular Epiretinal Membrane.....	274

10.10	Interpreting an Abnormal 10-2 Visual Field in a Patient with a Low Pretest Probability of Having Hydroxychloroquine Retinopathy.....	281
10.11	Summary of Key Points	283
	References.....	286
	Index.....	287



<http://www.springer.com/978-1-4939-0596-6>

Hydroxychloroquine and Chloroquine Retinopathy

Browning, D.J.

2014, XV, 291 p. 113 illus. in color., Hardcover

ISBN: 978-1-4939-0596-6